Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis
- PMID: 29237089
- PMCID: PMC6256937
- DOI: 10.1093/qjmed/hcx243
Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis
Abstract
Background/introduction: Sarcoidosis is a multi-systemic disorder of unknown etiology, characterized by the presence of non-caseating granulomas in target organs. In 90% of cases, there is thoracic involvement. Fifty to seventy percent of pulmonary sarcoidosis patients will experience acute, self-limiting disease. For the subgroup of patients who develop persistent disease, no targeted therapy is currently available.
Aim: To investigate the potential of the single nucleotide polymorphism (SNP), Toll-like receptor 3 Leu412Phe (TLR3 L412F; rs3775291), as a causative factor in the development of and in disease persistence in pulmonary sarcoidosis. To investigate the functionality of TLR3 L412F in vitro in primary human lung fibroblasts from pulmonary sarcoidosis patients.
Design: SNP-genotyping and cellular assays, respectively, were used to investigate the role of TLR3 L412F in the development of persistent pulmonary sarcoidosis.
Methods: Cohorts of Irish sarcoidosis patients (n = 228), healthy Irish controls (n = 263) and a secondary cohort of American sarcoidosis patients (n = 123) were genotyped for TLR3 L412F. Additionally, the effect of TLR3 L412F in primary lung fibroblasts from pulmonary sarcoidosis patients was quantitated following TLR3 activation in the context of cytokine and type I interferon production, TLR3 expression and apoptotic- and fibroproliferative-responses.
Results: We report a significant association between TLR3 L412F and persistent clinical disease in two cohorts of Irish and American Caucasians with pulmonary sarcoidosis. Furthermore, activation of TLR3 in primary lung fibroblasts from 412 F-homozygous pulmonary sarcoidosis patients resulted in reduced IFN-β and TLR3 expression, reduced apoptosis- and dysregulated fibroproliferative-responses compared with TLR3 wild-type patients.
Discussion/conclusion: This study identifies defective TLR3 function as a previously unidentified factor in persistent clinical disease in pulmonary sarcoidosis and reveals TLR3 L412F as a candidate biomarker.
Figures
Similar articles
-
The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2013 Dec 15;188(12):1442-50. doi: 10.1164/rccm.201304-0760OC. Am J Respir Crit Care Med. 2013. PMID: 24070541
-
Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2022 Mar 1;205(5):550-562. doi: 10.1164/rccm.202010-3880OC. Am J Respir Crit Care Med. 2022. PMID: 34985402
-
Association of TLR3 L412F Polymorphism with Cytomegalovirus Infection in Children.PLoS One. 2017 Jan 3;12(1):e0169420. doi: 10.1371/journal.pone.0169420. eCollection 2017. PLoS One. 2017. PMID: 28046022 Free PMC article.
-
The Relationship between TLR3 rs3775291 Polymorphism and Infectious Diseases: A Meta-Analysis of Case-Control Studies.Genes (Basel). 2023 Jun 21;14(7):1311. doi: 10.3390/genes14071311. Genes (Basel). 2023. PMID: 37510216 Free PMC article. Review.
-
Association of toll-like receptor 3 polymorphism rs3775291 with age-related macular degeneration: a systematic review and meta-analysis.Sci Rep. 2016 Jan 22;6:19718. doi: 10.1038/srep19718. Sci Rep. 2016. PMID: 26796995 Free PMC article. Review.
Cited by
-
Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?Front Pharmacol. 2024 Aug 30;15:1445923. doi: 10.3389/fphar.2024.1445923. eCollection 2024. Front Pharmacol. 2024. PMID: 39281278 Free PMC article. Review.
-
Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.J Clin Invest. 2024 Jan 2;134(1):e175264. doi: 10.1172/JCI175264. J Clin Invest. 2024. PMID: 38165044 Free PMC article. Review.
-
Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.Biomedicines. 2023 Nov 21;11(12):3109. doi: 10.3390/biomedicines11123109. Biomedicines. 2023. PMID: 38137330 Free PMC article.
-
Functional link between sarcoidosis-associated gene variants and quantitative levels of bronchoalveolar lavage fluid cell types.Front Med (Lausanne). 2023 Feb 7;10:1061654. doi: 10.3389/fmed.2023.1061654. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36824606 Free PMC article.
-
Immune mechanisms in fibrotic pulmonary sarcoidosis.Eur Respir Rev. 2022 Dec 21;31(166):220178. doi: 10.1183/16000617.0178-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36543347 Free PMC article. Review.
References
-
- Iannuzzi MC, Rybicki BA, Teirstein AS.. Sarcoidosis. N Engl J Med 2007; 357:2153–65. - PubMed
-
- Statement on Sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736–55. - PubMed
-
- Pietinalho A, Hiraga Y, Hosoda Y, Lofroos AB, Yamaguchi M, Selroos O.. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995; 12:61–7. - PubMed
-
- Chen ES, Moller DR.. Etiologies of sarcoidosis. Clin Rev Allergy Immunol 2015; 49:6–18. - PubMed
-
- Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P.. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156:4952–60. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources